Cochlear Hair Cell Promoter for Stable Targeted Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for sensorineural hearing loss face challenges in achieving stable and targeted gene expression in cochlear hair cells, with low transfection efficiency and lack of specificity, limiting their clinical effectiveness.
Innovation Solution
Development of a specific promoter, Otov-HC, comprising an enhancer sequence and core promoter element, which can guide gene expression specifically in cochlear hair cells, integrated into an AAV vector system for targeted delivery of deafness-related genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific ubiquitous promoters (CMV, CAG) are used for gene therapy, then gene expression can be achieved in cochlear cells, but the expression lacks targeting specificity and decreases over time due to transcriptional silencing
Solution Approach 1:
The patent applies local quality by designing a promoter with distinct functional modules: a hair cell-specific transcriptional activation domain (Otof-HC) combined with a ubiquitously active core promoter (CMV or CAG). This modular structure enables the promoter to specifically activate gene expression only in cochlear hair cells while maintaining stable long-term expression, resolving the contradiction between targeting specificity and expression stability.
2Productivity
If gene therapy is applied to cochlear hair cells, then hearing function can be restored, but transfection efficiency is low and genes cannot be stably expressed for a long time
Solution Approach 1:
The patent employs parameter changes by optimizing the promoter sequence composition and structure. Specifically, the Otof-HC activation domain contains optimized transcriptional regulatory elements that enhance binding affinity to hair cell-specific transcription factors, thereby increasing transfection efficiency and ensuring stable, long-term gene expression in cochlear hair cells.
3Reliability
If hearing aids or cochlear implants are used, then alternative treatment for deafness is provided, but the effectiveness is limited and cannot be compared with normal hearing
Solution Approach 1:
The patent applies mechanics substitution by replacing mechanical hearing assistance devices (hearing aids and cochlear implants) with a biological solution - gene therapy. By introducing functional genes into cochlear hair cells, the treatment restores natural hearing function at the cellular level, eliminating the need for external mechanical devices and achieving normal hearing effectiveness.
Data Source
Figure 1A~1E
Figure 2A~2E
Figure 3A~5
AI summary
The present invention relates to a cochlear hair cell specific promoter and the use thereof. The present invention particularly relates to a nucleic acid promoter (SEQ ID NO: 1), the nucleic acid promoter comprising an enhancer sequence (SEQ ID NO: 2) and a core promoter element (SEQ ID NO: 3), wherein the enhancer sequence has a sequence shown as SEQ ID NO: 2 or a sequence having at least 90% sequence identity with same, and the core promoter element has a sequence shown as SEQ ID NO: 3 or a sequence having at least 90% sequence identity with same. The promoter (SEQ ID NO: 1) can specifically guide gene expression in cochlear hair cells.